REDHILL BIOPHAR/S (NASDAQ:RDHL) Upgraded to Hold at BidaskClub
A number of other equities analysts have also recently commented on the company. HC Wainwright reaffirmed a buy rating and issued a $14.00 target price (down from $18.00) on shares of REDHILL BIOPHAR/S in a report on Thursday, March 5th. Zacks Investment Research raised REDHILL BIOPHAR/S from a hold rating to a buy rating and set a $4.75 target price on the stock in a report on Tuesday, March 17th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. REDHILL BIOPHAR/S presently has a consensus rating of Buy and an average price target of $14.75.
NASDAQ RDHL opened at $7.02 on Friday. The business’s fifty day moving average price is $7.02 and its 200-day moving average price is $5.95. The stock has a market capitalization of $259.58 million, a price-to-earnings ratio of -4.78 and a beta of 1.70. The company has a debt-to-equity ratio of 1.88, a current ratio of 5.83 and a quick ratio of 5.67. REDHILL BIOPHAR/S has a 1-year low of $3.26 and a 1-year high of $9.12.
A number of institutional investors have recently made changes to their positions in RDHL. D.A. Davidson & CO. bought a new position in REDHILL BIOPHAR/S in the 1st quarter worth $50,000. Meitav Dash Investments Ltd. purchased a new stake in REDHILL BIOPHAR/S in the 1st quarter worth $57,000. Jane Street Group LLC purchased a new stake in REDHILL BIOPHAR/S in the 1st quarter worth $95,000. Schonfeld Strategic Advisors LLC purchased a new stake in REDHILL BIOPHAR/S in the 4th quarter worth $104,000. Finally, Parametric Portfolio Associates LLC increased its stake in REDHILL BIOPHAR/S by 121.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 24,904 shares of the biotechnology company’s stock worth $113,000 after buying an additional 13,647 shares in the last quarter. 17.62% of the stock is currently owned by institutional investors.
REDHILL BIOPHAR/S Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.
Read More: What are the Benefits of Index Funds?
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.